CHRS Stock Summary and Trading Ideas (Coherus Oncology | NASDAQ:CHRS)

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Coherus Oncology trades on the NASDAQ stock market under the symbol CHRS.

As of October 28, 2026, CHRS stock price climbed to $1.16 with 1,196,826 million shares trading.

CHRS has a beta of 1.34, meaning it tends to be more sensitive to market movements. CHRS has a correlation of 0.05 to the broad based SPY ETF.

CHRS has a market cap of $179.22 million. This is considered a Micro Cap stock.

Last quarter Coherus Oncology reported $14 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.07.

In the last 3 years, CHRS traded as high as $3.73 and as low as $.66.

The top ETF exchange traded funds that CHRS belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

CHRS has underperformed the market in the last year with a return of -27.5%, while the SPY ETF gained +13.8%. In the last 3 month period, CHRS fell short of the market, returning -20.5%, while SPY returned +4.8%. However, in the most recent 2 weeks CHRS has outperformed the stock market by returning +8.4%, while SPY returned -0.7%.

CHRS support price is $1.02 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CHRS shares will trade within this expected range on the day.